News Classic

TORONTO, Nov. 26, 2024 /CNW/ – Lysander Funds Limited (“Lysander”) announces estimated cash distributions for each of Lysander-Slater Preferred Share ActivETF, Lysander-Canso Corporate Treasury ActivETF and Lysander-Canso Floating Rate ActivETF PR  LYCT LYFR, respectively (each, an “ETF” and collectively, the “ETFs”).

Estimated Tax Year ending December 15, 2024, Cash Distribution

The estimated tax year end cash distributions are based on information available as of October 31, 2024, and are subject to change.

The final tax year end cash distributions will be announced as soon as they are finalized for the tax year ending December 15, 2024, and will be based on the units outstanding on the record date of December 31, 2024. The actual taxable amounts of all distributions for 2024, including the tax characteristics of the monthly cash distributions, will be reported to investment dealers (through Clearing and Depository Services Inc. or “CDS”) in early 2025.

Commissions, trailing commissions, management fees and expenses all may be associated with investment funds. Please read the prospectus before investing. Investment funds are not guaranteed, their values change frequently, and past performance may not be repeated. Distributions are based on the actual number of units outstanding on the record date. Distributions are paid in cash and an investor that receives these distributions should expect that the value of their investment will decline over time. Distributions are not an indication of performance, rate of return or yield. If the Fund’s net income/capital gains is less than the amounts distributed in the tax year, the distribution will include a return of capital. 

®Lysander Funds is a registered trademark of Lysander Funds Limited.

SOURCE Lysander Funds Limited

View original content: http://www.newswire.ca/en/releases/archive/November2024/26/c9825.html

Editor’s note: This story was updated to add missing detail in the introduction and further updated to reflect approval of a cease-fire deal by Israel’s cabinet and U.S. President Joe Biden’s Tuesday afternoon announcement. Stock price action in the story has been updated and exchange and ticker info for the ISRA ETF has been corrected as well.

The governments of Israel and Lebanon have accepted a cease-fire deal, President Joe Biden said Tuesday.

“Today I have some good news to report from the Middle East,” Biden said, adding that he spoke with the prime ministers of Israel and Lebanon.

“I am pleased to announce that their governments have accepted the U.S. proposal to end the devastating conflict between Israel and Hezbollah,” said Biden, who made the remarks in the White House Rose Garden.

The cease-fire is set to take effect at 4 a.m. Wednesday, Biden said.

Hezbollah has not immediately commented on the deal announcement, the New York Times reported. Lebanon’s government does not control the Hezbollah militant group.

The deal calls for a 60-day truce, The New York Times reported, and would be overseen by the U.S., United Nations and others. Israel would withdraw forces from Lebanon and Hezbollah would move fighters to north of the Litani River.

Strikes between Israel and Hezbollah have continued during the cease-fire negotiations.

What Happened: The short-term proposal is to pause hostilities for 60 days but with the intention of a lasting truce, according to CNN, which cited an Israeli official.

Israeli Prime Minister Benjamin Netanyahu offered three reasons for the cease fire, one being to shift focus to Iran, replenish Israeli troops and put greater pressure on Hamas to release the hostages that were captured on Oct. 7, 2023.

See Also: Crude Oil Moves Lower; Dick’s Sporting Goods Earnings Top Views

Why It Matters: Not everyone is so confident the cease-fire will work.

Per the New York Times, Israel’s national security minister Itamar Ben-Gvir stressed the need for a “security zone” inside Lebanon to defend against Hezbollah. Otherwise, the two countries risk another war in the future, he said.

Ben-Gvir did not indicate that a cease-fire decision would cause him to leave Netanyahu’s coalition.

Market Reactions

Oil prices were trading down Tuesday, with the United States Oil Fund USO 0.65% lower at last check.

Israeli stocks, as monitored through the VanEck Israel ETF ISRA are up 23.5% year-to-date.

Other oil ETFs were in the red at last check Tuesday afternoon.

ProShares Ultra Bloomberg Crude Oil UCO fell by 0.93%, SPDR S&P Oil & Gas Exploration & Production ETF XOP was down 0.75% ahead of the closing bell and MicroSectorsTM Oil & Gas Exploration & Production 3X Leveraged ETNs OILU saw a 0.45% drop, according to Benzinga Pro.

Now Read:

Image: Shutterstock.

Investors with a lot of money to spend have taken a bullish stance on General Motors GM.

And retail traders should know.

We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don’t know. But when something this big happens with GM, it often means somebody knows something is about to happen.

So how do we know what these investors just did?

Today, Benzinga‘s options scanner spotted 66 uncommon options trades for General Motors.

This isn’t normal.

The overall sentiment of these big-money traders is split between 40% bullish and 39%, bearish.

Out of all of the special options we uncovered, 40 are puts, for a total amount of $2,717,669, and 26 are calls, for a total amount of $2,043,567.

What’s The Price Target?

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $35.0 to $80.0 for General Motors over the last 3 months.

Volume & Open Interest Trends

Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for General Motors’s options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of General Motors’s whale trades within a strike price range from $35.0 to $80.0 in the last 30 days.

General Motors Option Volume And Open Interest Over Last 30 Days

Largest Options Trades Observed:

About General Motors

General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company regained its us market share leader crown in 2022, after losing it to Toyota due to the chip shortage in 2021. 2023’s share was 16.5%. GM’s Cruise autonomous vehicle arm has previously done driverless geofenced AV robotaxi services in San Francisco and other cities but stopped in late 2023 after an accident. It restarted service in 2024 but not in California. GM owns over 80% of Cruise. GM Financial became the company’s captive finance arm in October 2010 via the purchase of AmeriCredit.

Present Market Standing of General Motors

• With a volume of 15,241,874, the price of GM is down -8.07% at $55.34.
• RSI indicators hint that the underlying stock may be approaching overbought.
• Next earnings are expected to be released in 63 days.

Unusual Options Activity Detected: Smart Money on the Move

Benzinga Edge’s Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for General Motors, Benzinga Pro gives you real-time options trades alerts.

Investors with a lot of money to spend have taken a bullish stance on Regeneron Pharmaceuticals REGN.

And retail traders should know.

We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don’t know. But when something this big happens with REGN, it often means somebody knows something is about to happen.

So how do we know what these investors just did?

Today, Benzinga‘s options scanner spotted 12 uncommon options trades for Regeneron Pharmaceuticals.

This isn’t normal.

The overall sentiment of these big-money traders is split between 58% bullish and 41%, bearish.

Out of all of the special options we uncovered, 8 are puts, for a total amount of $735,359, and 4 are calls, for a total amount of $167,575.

Expected Price Movements

After evaluating the trading volumes and Open Interest, it’s evident that the major market movers are focusing on a price band between $700.0 and $800.0 for Regeneron Pharmaceuticals, spanning the last three months.

Insights into Volume & Open Interest

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.

This data can help you track the liquidity and interest for Regeneron Pharmaceuticals’s options for a given strike price.

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Regeneron Pharmaceuticals’s whale activity within a strike price range from $700.0 to $800.0 in the last 30 days.

Regeneron Pharmaceuticals Call and Put Volume: 30-Day Overview

Largest Options Trades Observed:

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

In light of the recent options history for Regeneron Pharmaceuticals, it’s now appropriate to focus on the company itself. We aim to explore its current performance.

Regeneron Pharmaceuticals’s Current Market Status

• With a trading volume of 444,007, the price of REGN is down by -0.82%, reaching $743.4.
• Current RSI values indicate that the stock is may be oversold.
• Next earnings report is scheduled for 66 days from now.

What The Experts Say On Regeneron Pharmaceuticals

Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $1116.2.

Turn $1000 into $1270 in just 20 days?

20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access.
* An analyst from Truist Securities has decided to maintain their Buy rating on Regeneron Pharmaceuticals, which currently sits at a price target of $1126.
* An analyst from Citigroup downgraded its action to Neutral with a price target of $895.
* Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Regeneron Pharmaceuticals with a target price of $1215.
* Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on Regeneron Pharmaceuticals with a target price of $1195.
* In a cautious move, an analyst from Wolfe Research downgraded its rating to Outperform, setting a price target of $1150.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for Regeneron Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts.